David C. Linehan

机构：Cancer Institute (WIA), University of Rochester Medicine, AstraZeneca (Brazil), University of Rochester · ORCID：0000-0003-1859-2203

发表论文 411 篇 · 总被引 21143 次 · h-index 72

代表论文

• Platelet-activating factor (PAF) promotes immunosuppressive neutrophil differentiation within tumors (2024 · Proceedings of the National Academy of Sciences · 被引 37)
• CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models (2023 · Journal for ImmunoTherapy of Cancer · 被引 34)
• Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer (2024 · Molecular Therapy — Nucleic Acids · 被引 16)
• Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy (2024 · Hepatology Communications · 被引 14)
• New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy (2023 · Cell Death and Disease · 被引 13)
• Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1 (2023 · Cancers · 被引 13)